MBCO.F Stock Overview
A life sciences company, primarily focuses on the discovery and the development of synthetic derivative compound of a known proven drug.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Marvel Biosciences Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.12 |
| 52 Week High | CA$0.14 |
| 52 Week Low | CA$0.036 |
| Beta | 0.50 |
| 11 Month Change | 41.09% |
| 3 Month Change | 40.52% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 75.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| MBCO.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -3.8% | 1.8% |
| 1Y | n/a | 16.5% | 31.9% |
Return vs Industry: Insufficient data to determine how MBCO.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how MBCO.F performed against the US Market.
Price Volatility
| MBCO.F volatility | |
|---|---|
| MBCO.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MBCO.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine MBCO.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Rod Matheson | marvelbiotechnology.com |
Marvel Biosciences Corp., a life sciences company, primarily focuses on the discovery and the development of synthetic derivative compound of a known proven drug. The company’s lead compound MB-204, a novel fluorinated derivative of Istradefylline, which is a clinically approved adenosine A2a receptor antagonist used for the treatment of Parkinson’s disease. It targets diseases, such as depression, Alzheimer’s disease, and liver fibrosis due to non-alcoholic steatohepatitis.
Marvel Biosciences Corp. Fundamentals Summary
| MBCO.F fundamental statistics | |
|---|---|
| Market cap | US$3.99m |
| Earnings (TTM) | -US$1.56m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.6x
P/E RatioIs MBCO.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MBCO.F income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$2.10m |
| Earnings | -CA$2.10m |
Last Reported Earnings
Apr 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.047 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -54.4% |
How did MBCO.F perform over the long term?
See historical performance and comparison